Tafasitamab
| Tafasitamab | |
|---|---|
| Term | Tafasitamab |
| Short definition | Tafasitamab - (pronounced) (TA-fuh-SIH-tuh-mab) drug used with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma that have come back (come back) or have not improved after treatment with another cancer therapy. It is used in patients who cannot be treated with autologous stem cell transplantation. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Tafasitamab - (pronounced) (TA-fuh-SIH-tuh-mab) drug used with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma that have come back (come back) or have not improved after treatment with another cancer therapy. It is used in patients who cannot be treated with autologous stem cell transplantation. It is also being studied in the treatment of other types of cancer. Tafasitamab attaches to a protein called CD19, which is found on most B cells (a type of white blood cell) and some lymphoma cells. This can help the immune system kill cancer cells. Tafasitamab is a type of monoclonal antibody. Also called Monjuvi
External links
- Medical encyclopedia article on Tafasitamab
- Wikipedia's article - Tafasitamab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski